Business Wire·May 4, 2026, 4:05 PM ET

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Limited granted inducement awards of options to purchase up to 615,160 Class A Ordinary Shares to eight newly hired employees on April 30, 2026.
The awards were approved by the Compensation Committee & granted outside the 2023 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Each option has an exercise price of $5.08, matching the closing price of Zura's Class A Ordinary Shares on the grant date.
The options vest over four years, with 25% vesting on the first anniversary of the commencement date & the remainder vesting in equal quarterly installments thereafter.
Zura is a clinical-stage company developing dual-pathway antibodies for autoimmune & inflammatory diseases.
Lead candidate tibulizumab (ZB-106) is currently under evaluation in two Phase 2 studies: TibuSHIELD for hidradenitis suppurativa & TibuSURE for systemic sclerosis.
Additional candidates torudokimab (ZB-880) & crebankitug (ZB-168) have completed Phase 1/1b studies.